+关注
Walt3089
暂无个人介绍
IP属地：北京
27
关注
0
粉丝
2
主题
0
勋章
主贴
热门
Walt3089
2021-11-26
这结果。。。
抱歉，原内容已删除
Walt3089
2021-10-25
大概率
抱歉，原内容已删除
Walt3089
2021-04-08
$Takeda Pharmaceutical Co Ltd(TAK)$
跌跌不休为哪般？
Walt3089
2021-01-25
$Takeda Pharmaceutical Co Ltd(TAK)$
这么大量，涨幅不大啊
Walt3089
2021-01-01
还要脸吗？米国佬
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3554197581285961,"uuid":"3554197581285961","gmtCreate":1591103558956,"gmtModify":1604624011125,"name":"Walt3089","pinyin":"walt3089","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/bd3c278053307849b48984268911f507","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":27,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":2,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.43%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"北京","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":877674376,"gmtCreate":1637931039692,"gmtModify":1637931039692,"author":{"id":"3554197581285961","authorId":"3554197581285961","name":"Walt3089","avatar":"https://static.tigerbbs.com/bd3c278053307849b48984268911f507","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"这结果。。。","listText":"这结果。。。","text":"这结果。。。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877674376","repostId":"2186331055","repostType":2,"isVote":1,"tweetType":1,"viewCount":933,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856831082,"gmtCreate":1635168086597,"gmtModify":1635168086597,"author":{"id":"3554197581285961","authorId":"3554197581285961","name":"Walt3089","avatar":"https://static.tigerbbs.com/bd3c278053307849b48984268911f507","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"大概率","listText":"大概率","text":"大概率","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856831082","repostId":"2178429325","repostType":2,"isVote":1,"tweetType":1,"viewCount":824,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":348385892,"gmtCreate":1617889254516,"gmtModify":1617889254516,"author":{"id":"3554197581285961","authorId":"3554197581285961","name":"Walt3089","avatar":"https://static.tigerbbs.com/bd3c278053307849b48984268911f507","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TAK\">$Takeda Pharmaceutical Co Ltd(TAK)$</a>跌跌不休为哪般？","listText":"<a href=\"https://laohu8.com/S/TAK\">$Takeda Pharmaceutical Co Ltd(TAK)$</a>跌跌不休为哪般？","text":"$Takeda Pharmaceutical Co Ltd(TAK)$跌跌不休为哪般？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/348385892","isVote":1,"tweetType":1,"viewCount":1039,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":319246670,"gmtCreate":1611587517990,"gmtModify":1703751319671,"author":{"id":"3554197581285961","authorId":"3554197581285961","name":"Walt3089","avatar":"https://static.tigerbbs.com/bd3c278053307849b48984268911f507","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TAK\">$Takeda Pharmaceutical Co Ltd(TAK)$</a>这么大量，涨幅不大啊","listText":"<a href=\"https://laohu8.com/S/TAK\">$Takeda Pharmaceutical Co Ltd(TAK)$</a>这么大量，涨幅不大啊","text":"$Takeda Pharmaceutical Co Ltd(TAK)$这么大量，涨幅不大啊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/319246670","isVote":1,"tweetType":1,"viewCount":893,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":331164317,"gmtCreate":1609468343439,"gmtModify":1703739578936,"author":{"id":"3554197581285961","authorId":"3554197581285961","name":"Walt3089","avatar":"https://static.tigerbbs.com/bd3c278053307849b48984268911f507","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"还要脸吗？米国佬","listText":"还要脸吗？米国佬","text":"还要脸吗？米国佬","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/331164317","repostId":"1114476825","repostType":4,"isVote":1,"tweetType":1,"viewCount":1092,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0},"content":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":331164317,"gmtCreate":1609468343439,"gmtModify":1703739578936,"author":{"id":"3554197581285961","authorId":"3554197581285961","name":"Walt3089","avatar":"https://static.tigerbbs.com/bd3c278053307849b48984268911f507","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"还要脸吗？米国佬","listText":"还要脸吗？米国佬","text":"还要脸吗？米国佬","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/331164317","repostId":"1114476825","repostType":4,"isVote":1,"tweetType":1,"viewCount":1092,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0},"content":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":348385892,"gmtCreate":1617889254516,"gmtModify":1617889254516,"author":{"id":"3554197581285961","authorId":"3554197581285961","name":"Walt3089","avatar":"https://static.tigerbbs.com/bd3c278053307849b48984268911f507","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TAK\">$Takeda Pharmaceutical Co Ltd(TAK)$</a>跌跌不休为哪般？","listText":"<a href=\"https://laohu8.com/S/TAK\">$Takeda Pharmaceutical Co Ltd(TAK)$</a>跌跌不休为哪般？","text":"$Takeda Pharmaceutical Co Ltd(TAK)$跌跌不休为哪般？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/348385892","isVote":1,"tweetType":1,"viewCount":1039,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877674376,"gmtCreate":1637931039692,"gmtModify":1637931039692,"author":{"id":"3554197581285961","authorId":"3554197581285961","name":"Walt3089","avatar":"https://static.tigerbbs.com/bd3c278053307849b48984268911f507","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"这结果。。。","listText":"这结果。。。","text":"这结果。。。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877674376","repostId":"2186331055","repostType":2,"repost":{"id":"2186331055","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637928720,"share":"https://www.laohu8.com/m/news/2186331055?lang=&edition=full","pubTime":"2021-11-26 20:12","market":"us","language":"en","title":"Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2186331055","media":"Dow Jones","summary":"MW Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death","content":"<p>MW Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults</p>\n<p>Merck <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and partner Ridgeback Biotherapeutics said their COVID-19 antiviral molnupiravir reduced the risk of hospitalization or death in at-risk adults with mild-to-moderate COVID to 6.8% from 9.7% in the placebo group in the latest update of data from its study dubbed MOVe-OUT. That is equal to an absolute risk reduction of 3.0% and a relative risk reduction of 30%. \"Nine deaths were reported in the placebo group, and <a href=\"https://laohu8.com/S/AONE.U\">one</a> in the molnupiravir group,\" the companies said in a joint statement. \"The adverse event profile for molnupiravir remained consistent with the profile reported at the planned interim analysis.\" The companies have shared this latest data with the Food and Drug Administration, which is currently reviewing the data for a possible emergency use authorization for the treatment. Antiviral are expected to become a game changer in the pandemic as they can be easily taken at home, unlike existing treatments which must be administered either by infusion or subcutaneously in a clinical setting. Merck shares were down 2.8% premarket.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-26 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>MW Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults</p>\n<p>Merck <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and partner Ridgeback Biotherapeutics said their COVID-19 antiviral molnupiravir reduced the risk of hospitalization or death in at-risk adults with mild-to-moderate COVID to 6.8% from 9.7% in the placebo group in the latest update of data from its study dubbed MOVe-OUT. That is equal to an absolute risk reduction of 3.0% and a relative risk reduction of 30%. \"Nine deaths were reported in the placebo group, and <a href=\"https://laohu8.com/S/AONE.U\">one</a> in the molnupiravir group,\" the companies said in a joint statement. \"The adverse event profile for molnupiravir remained consistent with the profile reported at the planned interim analysis.\" The companies have shared this latest data with the Food and Drug Administration, which is currently reviewing the data for a possible emergency use authorization for the treatment. Antiviral are expected to become a game changer in the pandemic as they can be easily taken at home, unlike existing treatments which must be administered either by infusion or subcutaneously in a clinical setting. Merck shares were down 2.8% premarket.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","BK4550":"红杉资本持仓","MRK":"默沙东","BK4516":"特朗普概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186331055","content_text":"MW Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults\nMerck $(MRK)$ and partner Ridgeback Biotherapeutics said their COVID-19 antiviral molnupiravir reduced the risk of hospitalization or death in at-risk adults with mild-to-moderate COVID to 6.8% from 9.7% in the placebo group in the latest update of data from its study dubbed MOVe-OUT. That is equal to an absolute risk reduction of 3.0% and a relative risk reduction of 30%. \"Nine deaths were reported in the placebo group, and one in the molnupiravir group,\" the companies said in a joint statement. \"The adverse event profile for molnupiravir remained consistent with the profile reported at the planned interim analysis.\" The companies have shared this latest data with the Food and Drug Administration, which is currently reviewing the data for a possible emergency use authorization for the treatment. Antiviral are expected to become a game changer in the pandemic as they can be easily taken at home, unlike existing treatments which must be administered either by infusion or subcutaneously in a clinical setting. Merck shares were down 2.8% premarket.","news_type":1},"isVote":1,"tweetType":1,"viewCount":933,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":856831082,"gmtCreate":1635168086597,"gmtModify":1635168086597,"author":{"id":"3554197581285961","authorId":"3554197581285961","name":"Walt3089","avatar":"https://static.tigerbbs.com/bd3c278053307849b48984268911f507","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"大概率","listText":"大概率","text":"大概率","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/856831082","repostId":"2178429325","repostType":2,"repost":{"id":"2178429325","pubTimestamp":1635160298,"share":"https://www.laohu8.com/m/news/2178429325?lang=&edition=full","pubTime":"2021-10-25 19:11","market":"hk","language":"zh","title":"EMA启动对默沙东(MRK.US)新冠口服药的滚动审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2178429325","media":"智通财经","summary":"智通财经APP获悉，默沙东周一表示，欧洲药品管理局已启动对其新冠口服药 Molnupiravir 的滚动审评(rolling. 据悉，滚动审评是EMA在公共健康危机时期用于加快药品评估的一种方式，有利于更为快速的完成审评过程。FDA顾问小组将于11月底开会，讨论是否批准该药物。如果获得批准，该药物将成为首个新冠口服药。默沙东与美国政府签订了一份合同，以每疗程700美元的价格供应170万疗程。报道称，欧盟也在考虑签署药物供应协议。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/MRK\">默沙东</a>(MRK.US)周一表示，欧洲药品管理局(EMA)已启动对其新冠口服药 Molnupiravir 的滚动审评(rolling \nreview)。</p><p>据悉，滚动审评是EMA在公共健康危机时期用于加快药品评估的一种方式，有利于更为快速的完成审评过程。</p><p>早些时候，默沙东表示已向FDA申请 Molnupiravir \n的紧急授权。FDA顾问小组将于11月底开会，讨论是否批准该药物。如果获得批准，该药物将成为首个新冠口服药。</p><p>默沙东与美国政府签订了一份合同，以每疗程700美元的价格供应170万疗程。该公司最近还与英国、马来西亚和新加坡等国签署了供应协议。报道称，欧盟也在考虑签署药物供应协议。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EMA启动对默沙东(MRK.US)新冠口服药的滚动审评</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEMA启动对默沙东(MRK.US)新冠口服药的滚动审评\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-25 19:11 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/581589.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，默沙东(MRK.US)周一表示，欧洲药品管理局(EMA)已启动对其新冠口服药 Molnupiravir 的滚动审评(rolling \nreview)。据悉，滚动审评是EMA在公共健康危机时期用于加快药品评估的一种方式，有利于更为快速的完成审评过程。早些时候，默沙东表示已向FDA申请 Molnupiravir \n的紧急授权。FDA顾问小组将于11月底开会，讨论是否批准该药物。如果...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/581589.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/8063c97727cb21de0867e6829ff807e3","relate_stocks":{"MRK":"默沙东"},"source_url":"http://www.zhitongcaijing.com/content/detail/581589.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2178429325","content_text":"智通财经APP获悉，默沙东(MRK.US)周一表示，欧洲药品管理局(EMA)已启动对其新冠口服药 Molnupiravir 的滚动审评(rolling \nreview)。据悉，滚动审评是EMA在公共健康危机时期用于加快药品评估的一种方式，有利于更为快速的完成审评过程。早些时候，默沙东表示已向FDA申请 Molnupiravir \n的紧急授权。FDA顾问小组将于11月底开会，讨论是否批准该药物。如果获得批准，该药物将成为首个新冠口服药。默沙东与美国政府签订了一份合同，以每疗程700美元的价格供应170万疗程。该公司最近还与英国、马来西亚和新加坡等国签署了供应协议。报道称，欧盟也在考虑签署药物供应协议。","news_type":1},"isVote":1,"tweetType":1,"viewCount":824,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":319246670,"gmtCreate":1611587517990,"gmtModify":1703751319671,"author":{"id":"3554197581285961","authorId":"3554197581285961","name":"Walt3089","avatar":"https://static.tigerbbs.com/bd3c278053307849b48984268911f507","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TAK\">$Takeda Pharmaceutical Co Ltd(TAK)$</a>这么大量，涨幅不大啊","listText":"<a href=\"https://laohu8.com/S/TAK\">$Takeda Pharmaceutical Co Ltd(TAK)$</a>这么大量，涨幅不大啊","text":"$Takeda Pharmaceutical Co Ltd(TAK)$这么大量，涨幅不大啊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/319246670","isVote":1,"tweetType":1,"viewCount":893,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
